Clarus Therapeutics Holdings, Inc.
CRXTQ
Other OTC0.00
USD
- -
- -
CIK
0001817944
Return %
Stock
S&P500
1Y
-99.93
26.53
3Y
-99.99
76.60
5Y
-99.99
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Robert E. Dudley
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 555 Skokie Boulevard Northbrook IL United States of America 60062
- IPO Date
- Feb 9, 2021
- CIK
- 0001817944
- Website
- clarustherapeutics.com
- Similar Companies
- Business
- Clarus Therapeutics Holdings, Inc. (CRXTQ) operates as a pharmaceutical company focused on the development and commercialization of androgen and metabolic therapies, primarily oral testosterone replacement products for men in the United States. The company offers JATENZO, a soft gel oral formulation of testosterone undecanoate indicated for treating hypogonadal men; licensing agreements for androgen therapies targeting inflammatory breast disease and certain breast cancers via HavaH Therapeutics, and proprietary technology from The Royal Institution for the Advancement of Learning/McGill University to address CoQ10 deficiency-related conditions. Founded in 2003 and headquartered in Northbrook, Illinois, Clarus targets endocrinology and men's health segments with operations centered in the U.S. In recent major changes, Clarus Therapeutics filed for voluntary Chapter 11 reorganization on September 5, 2022, in the U.S. Bankruptcy Court for the District of Delaware, followed by a court-supervised auction of JATENZO assets concluding on October 14, 2022; implemented a roughly 40% workforce reduction including sales personnel and discontinued certain R&D activities and the HavaH Therapeutics partnership in August 2022; and completed its plan of liquidation effective February 28, 2023, resulting in the company going out of business.